Browse studies
Find your next paid study
4 recruiting studies matching your filters
Precision Medicine Approaches to Renal Osteodystrophy
Treatment of renal osteodystrophy is impeded by the lack of practical and accurate tools to determine underlying bone turnover. Gold standard bone biopsy is no…
Renal OsteodystrophyChronic Kidney DiseasesCKD-MBD+2 more
Estimated
~$10 – $1,125
Thomas NickolasNCT05880914
A Phase 2 Biomarker Study of Parathyroid Tumor Clonal Status in Hyperparathyroid Disorders (Primary, Secondary, and Tertiary)
To define the frequency of monoclonal-X and polyclonal-X tumors in hyperparathyroid disorders patients having PTX and to define the relationship between parath…
Parathyroid TumorPrimary HyperparathyroidismSecondary Hyperparathyroidism (SHPT)+1 more
Estimated
~$10 – $750
Washington University School of MedicineNCT05997810
Phase 3
Phase 3, Randomized, Open-label, Controlled, Multiple Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 Days to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis
This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
Secondary HyperparathyroidismChronic Kidney Disease
Estimated
~$10 – $7,500
AmgenNCT03633708
Phase 2
An Open-Label, Randomized, Multiple-Dose, Multi-Center Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of CTAP101 Extended-release Capsules in Pediatric Participants <18 Years of Age With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyr…
CKD Stage 3CKD Stage 4Secondary Hyperparathyroidism+1 more
Estimated
~$10 – $8,750
OPKO Health, Inc.NCT07494045